title: Guillain-Barré syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009.
abstract: Using data from Vaccine Adverse Event Reporting System, we identified 69 reports of Guillain-Barré Syndrome (GBS) after Gardasil vaccination that occurred in the United States between 2006 and 2009. The onset of symptoms was within 6 weeks after vaccination in 70% of the patients in whom the date of vaccination was known. The estimated weekly reporting rate of post-Gardasil GBS within the first 6 weeks (6.6 per 10,000,000) was higher than that of the general population, and higher than post-Menactra and post-influenza vaccinations. Further prospective active surveillance for accurate ascertainment and identification of high-risk groups of GBS after Gardasil vaccination is warranted.
authors.affiliation: Department of Neurology, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA. souayani@umdnj.edu
authors.forename: Nizar
authors.initials: N
authors.lastname: Souayah
authors.forename: P A
authors.initials: PA
authors.lastname: Michas-Martin
authors.forename: Abu
authors.initials: A
authors.lastname: Nasar
authors.forename: Nataliya
authors.initials: N
authors.lastname: Krivitskaya
authors.forename: Hussam A
authors.initials: HA
authors.lastname: Yacoub
authors.forename: Hafiz
authors.initials: H
authors.lastname: Khan
authors.forename: Adnan I
authors.initials: AI
authors.lastname: Qureshi
mesh_terms: D000293:Adolescent; D002648:Child; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000453:epidemiology*; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines